$46.25
arrow_drop_down5.77%Key Stats | |
---|---|
Open | $48.89 |
Prev. Close | $49.02 |
EPS | -2.41 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 45.83 | 49.54 |
52 Week Range | 9.60 | 53.27 |
Ratios | |
---|---|
EPS | -2.41 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Kymera Therapeutics Announces Pricing of $225 Million Public Offering
Kymera Therapeutics soars as Sanofi expands phase 2 trials By Investing.com - Investing.com Australia
Why Kymera Therapeutics Stock Is Soaring Today - The Motley Fool
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
Kymera Therapeutics to Participate in Upcoming June Investor Conferences